This means that passive immunization with tau antibodies is usually a feasible therapeutic focus on and the CSF level of p-tau262/356 or from the microtubule binding domain (MTBD) can serve as a practical biomarker of tau pathology to monitor tau therapeutics in clinical trials.Immerse oneself in TAU’s bold and emotionally billed will work, where… Read More